ROCHESTER, N.Y., Oct. 20, 2015 (GLOBE NEWSWIRE) -- Vaccinex Inc., a clinical-stage biotechnology company engaged in the discovery and development of therapeutic monoclonal antibodies to treat cancer and neurodegenerative diseases, today announced publication of a manuscript entitled "Safety, Pharmacokinetics and Pharmacodynamics of a Humanized anti-Semaphorin 4D Antibody in a First-In-Human Study of Patients with Advanced Solid Tumors" in the journal Clinical Cancer Research (2015 Oct 7). The antibody, termed VX15/2503, was found to be well tolerated in this patient population and conformed to expected PD profile. In addition, one patient exhibited a partial response, 45% of patients had stable disease for at least 8 weeks and 19% were found to have stable disease for at least 16 weeks. Vaccinex is actively planning follow-on studies of combination therapy of VX15/2503 with a checkpoint inhibitor in selected cancer indications which they intend to initiate in 1H 2016. "In prior preclinical studies, the combination of anti-semaphorin 4D antibody with a checkpoint inhibitor has been shown to strikingly eradicate tumors. The importance of the safety profile reported in the present study is that it strongly supports continued development of this novel combination therapy as a potentially promising cancer treatment. We look forward to initiating a phase 1b/2 clinical trial focused on efficacy in early 2016." Maurice Zauderer, CEO.
About Vaccinex, Inc.
Vaccinex, Inc. is a privately held clinical-stage immunotherapy company engaged in the discovery and development of human therapeutic monoclonal antibodies to treat cancer and neurodegenerative diseases. The Company has completed phase 1 clinical trials in solid tumors and multiple sclerosis and is currently engaged in a phase 2 clinical trial in Huntington's disease. Vaccinex utilizes its proprietary ActivMAb® Antibody Discovery Technology for rapid, mammalian cell-based antibody selection to build its antibody pipeline and in service to its biopharmaceutical partners. ActivMAb® combines the advantages of rapid and sensitive selection by virus panning and cell sorting in one technology, with intrinsic selection of antibodies that are efficiently expressed in mammalian cells and have desirable solubility and stability properties. Vaccinex is based in Rochester, New York. For more information and to contact Vaccinex, visit www.vaccinex.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements reflecting the current beliefs and expectations of management. Words such as "may," "believe," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions, as well as other words or expressions referencing future events, conditions or circumstances, are intended to identify forward-looking statements. Forward-looking statements contained in this press release include statements about the initiation of a Phase 2 clinical trial for the Company's lead monoclonal antibody, VX15/2503. Forward-looking statements in this press release involve substantial risks and uncertainties that could cause our performance or achievements to differ significantly from those expressed or implied by the forward-looking statements, including as a result of the inherent challenges in clinical development. All forward-looking statements are based on Vaccinex's expectations and assumptions as of the date of this press release, and actual results may differ materially. Except as required by law, Vaccinex expressly disclaims any responsibility to update any forward-looking statement contained herein, whether as a result of new information, future events or otherwise.
CONTACT: Vaccinex email@example.com